Recruiting

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(61 sites)

United States

Banner MD Anderson Cancer Center, Gilbert, Arizona

Genesis Cancer and Blood Institute, Hot Springs, Arkansas

Alta Bates Summit Medical Center, Berkeley, California

City of Hope, Duarte, California

Cedars-Sinai Medical Center, Los Angeles, California

University of California, Los Angeles, Los Angeles, California

University of California, Davis Comprehensive Cancer Center, Sacramento, California

University of California, San Diego, San Diego, California

University of California, San Francisco, San Francisco, California

Rocky Mountain Cancer Centers, Denver, Colorado

Medical Oncology Hematology Consultants, Newark, Delaware

MedStar Georgetown University Hospital, Washington D.C., District of Columbia

Miami Cancer Institute at Baptist Health, Inc., Miami, Florida

Advent Health Cancer Institute, Orlando, Florida

Orlando Health Cancer Institute, Orlando, Florida

Moffitt Cancer Center, Tampa, Florida

Augusta University Georgia Cancer Center, Augusta, Georgia

Rush University Medical Center, Chicago, Illinois

Indiana Blood and Marrow Transplantation, Indianapolis, Indiana

The University of Kansas Hospital, Kansas City, Kansas

University of Kentucky Medical Center, Lexington, Kentucky

University of Louisville Health Brown Cancer Center, Louisville, Kentucky

Norton Cancer Institute, Louisville, Kentucky

The Center for Cancer and Blood Disorders, Bethesda, Maryland

Massachusetts General Hospital, Boston, Massachusetts

Beth Israel Deaconess Medical Center, Boston, Massachusetts

University of Missouri - Ellis Fischel Cancer Center, Columbia, Missouri

MidAmerica Cancer Care, Kansas City, Missouri

Washington University School of Medicine - Siteman Cancer Center, St Louis, Missouri

Astera Cancer Care, East Brunswick, New Jersey

John Theurer Cancer Center, Hackensack, New Jersey

Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey

Columbia University Irving Medical Center and New York-Presbyterian Hospital, New York, New York

University of Rochester Medical Center, Rochester, New York

Novant Health Cancer Institute- Hematology, Charlotte, North Carolina

Duke Blood Cancer Center, Durham, North Carolina

Oncology Hematology Care - Kenwood, Cincinnati, Ohio

University of Cincinnati Medical Center, Cincinnati, Ohio

Cleveland Clinic, Cleveland, Ohio

Oncology Associates of Oregon, Eugene, Oregon

Oregon Health and Science University, Portland, Oregon

Fox Chase Cancer Center, Philadelphia, Pennsylvania

Avera Cancer Institute, Sioux Falls, South Dakota

Vanderbilt University Medical Center, Nashville, Tennessee

Texas Oncology - Central South, Austin, Texas

Texas Oncology - Dallas Fort Worth, Dallas, Texas

MD Anderson Cancer Center, Houston, Texas

Texas Transplant Institute, San Antonio, Texas

Texas Oncology - Tyler, Tyler, Texas

Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah

Intermountain Health LDS Hospital, Salt Lake City, Utah

University of Virginia, Charlottesville, Virginia

Virginia Cancer Specialists, Fairfax, Virginia

Virginia Oncology Associates - Norfolk, Norfolk, Virginia

Swedish Cancer Institute, Seattle, Washington

Fred Hutchinson Cancer Center, Seattle, Washington

Canada

Arthur JE Child Comprehensive Cancer Centre, Calgary, Alberta

Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia

Princess Margaret Cancer Centre - University Health Network, Toronto, Ontario

CHUM - University of Montreal Hospital Centre, Montreal, Quebec

Hopital de'L'Enfant-Jesus, Québec, Quebec

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

Trial locations(61 sites)

Interested in joining?